MedPath

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

Not Applicable
Active, not recruiting
Conditions
Infections
Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions
Dietary Supplement: vitamin D3
Dietary Supplement: fish oil placebo
Dietary Supplement: Vitamin D3 placebo
Registration Number
NCT01758081
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18 levels.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
25874
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
vitamin D + fish oil placebovitamin D3vitamin D3 + fish oil placebo
vitamin D + fish oilvitamin D3vitamin D3 + Omacor
vitamin D + fish oilomega-3 fatty acids (fish oil)vitamin D3 + Omacor
vitamin D + fish oil placebofish oil placebovitamin D3 + fish oil placebo
vitamin D placebo + fish oilomega-3 fatty acids (fish oil)vitamin D placebo + Omacor
vitamin D placebo + fish oilVitamin D3 placebovitamin D placebo + Omacor
vitamin D placebo + fish oil placeboVitamin D3 placebovitamin D placebo + fish oil placebo
vitamin D placebo + fish oil placebofish oil placebovitamin D placebo + fish oil placebo
Primary Outcome Measures
NameTimeMethod
upper respiratory infectionone year
hCAP-18one year
Secondary Outcome Measures
NameTimeMethod
lower respiratory infection5 years
urinary tract infection5 years
cellulitis5 years
antimicrobial-treated infection5 years
infection-related hospitalizations5 years

Trial Locations

Locations (1)

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath